Abstract: A hearing aid device is disclosed. The hearing aid device comprises means to improve, augment and/or protect the hearing capability of a user by receiving acoustic signals from the surroundings of the user, generating corresponding audio signals, possibly modifying the audio signals and providing the possibly modified audio signals as audible signals to at least one of the user's ears. The hearing aid device comprises a sensor member for detecting the movement and/or acceleration and/or orientation (or spatial position) of the hearing aid device. The hearing aid device comprises at least two hearing aid microphones and a control unit for determining the position or a deviation from an intended position of the hearing aid device or hearing aid microphones. The hearing aid device is configured to compensate for a possible dislocation of the hearing aid microphones.

Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

Abstract: Provided are methods of treating feline Coronavirus infections comprising administering a therapeutically effective amount of a compound of Compound 1 to Compound 9, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

Abstract: The present invention provides compositions and methods for detecting mutations associated with blood type determination in the cat.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of VS-FCV.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of hFCV.

Abstract: The present invention provides compositions and methods for detecting mutations associated with blood type determination in the cat.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, a typical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of hFCV.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of VS-FCV.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of VS-FCV.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a hemorrhagic feline calicivirus (hFCV), a novel, a typical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of hFCV.

Abstract: Compositions derived from a novel viral isolate designated feline T-lymphotropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

Abstract: A tester applies a high-voltage test signal across the probes of a high-voltage measuring apparatus, wherein at least one of the probes is mounted at a probe end of an elongated insulated pole. The tester includes a battery-powered generator for generating the test signal which is applied across two contact terminals, respectively adapted for connection to the probes. One of the contact terminals is disposed at the bottom of an elongated tubular socket which receives the probe end of the pole, the contact terminal including two conductive members spring-biased apart until the pole is inserted in the socket. The generator is energized through a switch which may be mounted on the generator housing. In one embodiment the other contact terminal is an alligator clip and in a second embodiment the other contact terminal is disposed in a second socket.

Abstract: Compositions derived from a novel viral isolate designated feline immunodeficiency virus (FIV) include the whole virus, proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FIV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses inactivated cell lines expressing FIV antigens, and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

Abstract: The ammeter includes a tubular housing with a hook-shaped sensor secured thereto at one end thereof and coupled to battery-powered digital ammeter circuitry disposed within the housing. The other end of the housing is open and receives telescopically therein a cylindrical cartridge which includes either a cradle or a recess supporting a replaceable battery and carrying connectors for connecting the battery to the ammeter circuitry. A universal spline coupler is telescopically received in a bore in the cartridge and projects from the tubular housing when the cartridge is disposed therein for coupling to associated equipment, such as a hot stick.

Abstract: Compositions derived from a novel viral isolate designated feline T-lymphotropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

Abstract: Compositions derived from a novel viral isolate designated feline T-lymphototropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

Abstract: A cable connector jacket formed of flexible, electrically insulating plastic is of unitary, one-piece construction, including two cavity-defining bodies hingedly interconnected in a clamshell-type configuration for movement between open and closed conditions. Each body has two pairs of channel-like tapered arms respectively extending in opposite directions therefrom generally parallel to the hinge line. When the bodies are in their closed conditions, the cavities define a chamber for accommodating the cable connector, and the arms of one body respectively mate with those of the other body to form four tapered tubes for respectively accommodating cable portions interconnected by the connector. A latch on the body holds the jacket closed.

Abstract: A novel feline fibroblastic cell line infected with Snyder-Theilen feline leukemia virus is provided. The cell line produces large amounts of FeLV when cultured in a medium free from serum supplement. The latter aspect is a substantial advantage since it reduces the expense of culturing and eliminates the need to separate serum from culture medium prior to preparing a vaccine.Feline fibroblastic cell line FF64/280 was deposited at the American Type Culture Collection on Apr. 17, 1984, and granted accession no. VR 2085.